Business Insider
My Markets Watchlist
Markets Stocks

Astellas Pharma Inc. Stock , ALPMF

1,416.50 JPY -2.50 -0.18%
02:30:00 AM TOKIO
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar


Astellas Pharma Stock Snapshot

17.66 B
Market Cap in USD
1.79 B
Number of Shares
1.79 B
Total Number of Shares
74.00
Dividend in JPY
5.12
Dividend Yield
51.03
P/E Ratio
95.54
Free Float in %
28.35
EPS in JPY
845.25
Book Value per Share in JPY
112.18
Cash Flow per Share in JPY

Astellas Pharma Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
Date Analyst Rating Price

Astellas Pharma Estimates* in JPY

  2026 2027 2028 2029 2030
Revenue 1,949,282 2,046,751 1,892,568 1,632,183 1,537,383
Dividend 79.08 82.77 86.00 83.00 84.67
Dividend Yield (in %) 5.58 % 5.84 % 6.07 % 5.86 % 5.97 %
EPS 81.11 117.38 122.38 85.42 77.65
P/E Ratio 17.48 12.08 11.58 16.59 18.25
EBIT 203,979 290,113 284,200 208,833 184,267
EBITDA 431,791 505,940 476,729 367,350 330,450
Net Profit 145,243 210,191 209,743 152,433 134,867
Net Profit Adjusted - - 384,900 - -
Pre-Tax Profit 191,393 282,889 272,584 194,750 161,350
Pre-Tax Profit Reported 187,338 313,460 302,640 334,200 293,300
EPS (Non-GAAP) ex. SOE - - - - -
EPS (GAAP) 83.32 113.16 87.98 86.29 84.10
Gross Income 1,578,038 1,636,478 1,560,867 1,280,550 1,212,950
Cash Flow from Investing -61,820 -61,791 -67,967 -73,100 -74,100
Cash Flow from Operations 373,932 408,960 473,769 428,567 379,800
Cash Flow from Financing -215,921 -222,401 -247,326 -236,835 -211,835
Cash Flow per Share 205.32 217.69 207.09 - -
Free Cash Flow 279,440 321,600 364,700 344,750 364,200
Free Cash Flow per Share 218.30 230.90 268.60 235.80 203.40
Book Value per Share 853.36 897.90 918.10 935.05 908.25
Net Debt 382,888 242,257 -54,787 -494,700 -715,700
Research & Development Exp. 348,622 354,625 345,202 - -
Capital Expenditure 51,200 52,200 64,840 58,100 59,100
Selling, General & Admin. Exp. 928,060 927,630 861,830 902,800 872,050
Shareholder’s Equity 1,503,877 1,572,939 1,653,803 1,673,897 1,626,363
Total Assets 3,387,601 3,419,226 3,375,450 3,125,097 2,988,913
  Previous Quarter
ending 03/31/25 		Current Quarter
ending 06/30/25 		Next Quarter
ending 09/30/25 		Current Year
ending 03/31/26 		Next Year
ending 03/31/27
Earnings Estimates
No. of Analysts - 3 3 11 11
Average Estimate - 19.970 JPY 24.398 JPY 81.112 JPY 117.385 JPY
Year Ago - 21.001 JPY 20.061 JPY 28.347 JPY -
Publish Date - - - - -
Revenue Estimates
No. of Analysts - 5 5 13 13
Average Estimate - 468,204 JPY 476,234 JPY 1,949,282 JPY 2,046,751 JPY
Year Ago - 473,124 JPY 462,497 JPY 1,912,323 JPY -
Publish Date - - - - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. JPY

2025 2024 2023 2022 2021 2020 2019
Sales 1,912,323.00 1,603,672.00 1,518,619.00 1,296,163.00 1,249,528.00 1,300,843.00 1,306,348.00
Change of sales in % 19.25 5.60 17.16 3.73 -3.94 -0.42 0.46
Gross profit on sales 1,426,355.00 1,212,367.00 1,191,830.00 1,014,871.00 979,702.00 1,002,940.00 979,086.00
Gross profit on sales change in % 17.65 1.72 17.44 3.59 -2.32 2.44 0.91
Operating income 255,672.00 178,070.00 285,430.00 220,021.00 250,897.00 281,106.00 280,141.00
Operating income change in % 43.58 -37.61 29.73 -12.31 -10.75 0.34 3.28
Income before tax 31,496.00 28,134.00 131,101.00 156,397.00 144,846.00 245,350.00 248,967.00
Income before tax change in % 11.95 -78.54 -16.17 7.97 -40.96 -1.45 14.15
Income after tax 50,747.00 17,045.00 98,714.00 124,086.00 120,589.00 195,411.00 222,265.00
Income after tax change in % 197.72 -82.73 -20.45 2.90 -38.29 -12.08 34.97

Balance Sheet in Mio. JPY

2025 2024 2023 2022 2021 2020 2019
Total liabilities 1,826,290.00 1,973,616.00 948,564.00 872,086.00 887,514.00 1,028,990.00 639,252.00
Long-term liabilities per share 427.12 383.63 123.85 101.08 159.28 123.97 75.08
Equity 1,513,255.00 1,595,988.00 1,507,954.00 1,460,308.00 1,386,115.00 1,289,168.00 1,258,396.00
Equity change in % -5.18 5.84 3.26 5.35 7.52 2.45 -0.78
Balance sheet total 3,339,544.00 3,569,604.00 2,456,518.00 2,332,394.00 2,273,629.00 2,318,158.00 1,897,648.00
Balance sheet total change in % -6.44 45.31 5.32 2.58 -1.92 22.16 2.12

Key Data in JPY

2025 2024 2023 2022 2021 2020 2019
Sales per share 1,064.08 891.10 832.09 700.40 672.44 692.84 675.55
P/E ratio (year end quote, basic EPS) 51.03 172.91 34.72 28.49 26.21 16.04 14.42
P/E ratio (year end quote, diluted EPS) 51.23 173.53 34.81 28.50 26.23 16.06 14.43
Dividend yield in % 5.12 4.26 3.19 2.62 2.47 2.39 2.29
Equity ratio in % 45.31 44.71 61.39 62.61 60.96 55.61 66.31
Debt ratio in % 54.69 55.29 38.61 37.39 39.04 44.39 33.69

Astellas Pharma Dividend Calendar

Date Name Dividend *yield Currency
2025 Astellas Pharma Inc. 74.00 5.12 JPY
2024 Astellas Pharma Inc. 70.00 4.26 JPY
2023 Astellas Pharma Inc. 60.00 3.19 JPY
2022 Astellas Pharma Inc. 50.00 2.62 JPY
2021 Astellas Pharma Inc. 42.00 2.47 JPY
2020 Astellas Pharma Inc. 40.00 2.39 JPY
2019 Astellas Pharma Inc. 38.00 2.29 JPY
2018 Astellas Pharma Inc. 36.00 2.23 JPY
2017 Astellas Pharma Inc. 34.00 2.32 JPY
2016 Astellas Pharma Inc. 32.00 2.14 JPY
2015 Astellas Pharma Inc. 30.00 1.52 JPY
2014 Astellas Pharma Inc. 27.00 2.21 JPY
2013 Astellas Pharma Inc. 26.00 2.57 JPY
2012 Astellas Pharma Inc. 25.00 3.68 JPY
2011 Astellas Pharma Inc. 25.00 4.06 JPY
2010 Astellas Pharma Inc. 25.00 3.69 JPY
2009 Astellas Pharma Inc. 24.00 3.97 JPY
*Yield of the Respective Date

Astellas Pharma Calendar

Event Estimate Info Date
Annual General Meeting 28.350 JPY Annual General Meeting 06/19/2025
Earnings Report 21.000 JPY Q1 2025 Earnings Release 07/30/2025
Earnings Report 20.060 JPY Q2 2025 Earnings Release 10/29/2025
Earnings Report -54.550 JPY Q3 2025 Earnings Release 02/09/2026
Earnings Report 41.840 JPY Q4 2025 Earnings Release 04/23/2026

Astellas Pharma Past Events

Event Actual EPS Info Date
Earnings Report -18.560 JPY Q4 2024 Earnings Release 04/25/2025
Earnings Report 8.090 JPY Q3 2024 Earnings Release 02/04/2025
Earnings Report -0.810 JPY Q2 2024 Earnings Release 10/30/2024
Earnings Report 18.460 JPY Q1 2024 Earnings Release 08/01/2024
Annual General Meeting 9.510 JPY Annual General Meeting 06/20/2024
Earnings Report -25.490 JPY Q4 2023 Earnings Release 04/25/2024
Earnings Report 26.560 JPY Q3 2023 Earnings Release 02/05/2024
Earnings Report 39.300 JPY Q2 2023 Earnings Release 11/01/2023
Earnings Report 13.590 JPY Q1 2023 Earnings Release 08/01/2023
Annual General Meeting 54.240 JPY Annual General Meeting 06/22/2023
Earnings Report -4.570 JPY Q4 2022 Earnings Release 04/27/2023
Earnings Report 32.860 JPY Q3 2022 Earnings Release 02/06/2023
Earnings Report 22.090 JPY Q2 2022 Earnings Release 10/31/2022
Earnings Report 16.560 JPY Q1 2022 Earnings Release 08/01/2022
Annual General Meeting 67.080 JPY Annual General Meeting 06/20/2022
Earnings Report -6.640 JPY Q4 2021 Earnings Release 04/27/2022
Earnings Report 32.340 JPY Q3 2021 Earnings Release 02/02/2022

Astellas Pharma Profile

Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products: XTANDI, PADCEV, XOSPATA, VYLOY, VEOZAH, IZERVAY, EVRENZO, BETANIS and PROGRAF. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
2
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Astellas Pharma Management

Name Job
Kenji Yasukawa Chairman
Claus Gerhard Zieler Chief Commercial & Medical Affairs Officer
Nick Eshkenazi Chief Digital & Transformation Officer
Kitamura Atsushi Chief Financial Officer
Rao V. Mantri Chief Manufacturing Officer
Tadaaki Taniguchi Chief Research & Development Officer
Adam John Pearson Chief Strategy Officer
Rika Hirota Director
Tatjana Dragovic General Counsel, Chief Ethics & Compliance Officer
Yasuhiro Fujita Head-Accounting & Global Business Solutions
Mika Nakayama Independent Outside Director
Yoichi Ohno Independent Outside Director
Eriko Sakurai Independent Outside Director
Takashi Tanaka Independent Outside Director
Tomoko Aramaki Independent Outside Director
Masahiro Miyazaki Independent Outside Director
Rie Akiyama Independent Outside Director
Naoki Okamura President, CEO & Representative Director
Katsuyoshi Sugita Representative Director & Chief People Officer
Eisuke Nozawa Vice President-Regulatory Affairs